Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Market Share, Market Insights and Outlook, H1 2016: Hexa Reports

Submitted by: Submitted by

Views: 10

Words: 1010

Pages: 5

Category: Business and Industry

Date Submitted: 07/07/2016 12:54 AM

Report This Essay

Hexa Reports

Market Research Reports and Insightful Company Profiles

Metastatic Hormone Refractory (Castration Resistant,

Androgen-Independent) Prostate Cancer Market Size,

Share, Global Analysis, Trends, Outlook, Overview, Market

Insights, Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent)

Prostate Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Hormone

Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with

analysis by stage of development, drug target, mechanism of action (MoA), route of administration

(RoA) and molecule type.

Browse Detail Report With TOC @ http://hexareports.com/report/metastatic-hormone-refractorycastration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2016/details

The report also covers the descriptive pharmacological action of the therapeutics, its complete research

and development history and latest news and press releases. Additionally, the report provides an

overview of key players involved in therapeutic development for Metastatic Hormone Refractory

(Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued

projects.

Hexa Reports

Market Research Reports and Insightful Company Profiles

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy

areas and nearly 3,000 indications. The report is built using data and information sourced from Global

Markets Direct's proprietary databases, company/university websites, clinical trial registries,

conferences, SEC filings, investor presentations and featured press releases from company/university

sites and industry-specific third party sources.

Drug...